MediMix’s Post

RYBREVANT plus LAZCLUZE versus osimertinib in EGFR-mutated advanced lung cancer🩺 New data from the Phase 3 MARIPOSA study, presented at IASLC 2024, shows that RYBREVANT (amivantamab-vmjw) combined with LAZCLUZE (lazertinib) significantly improves long-term survival compared to osimertinib in EGFR-mutant advanced lung cancer. Johnson & Johnson Joshua Bauml Shirish Gadgeel For more details, visit https://lnkd.in/eYJwsVU3 #lcsm #LungCancer #OncoDaily #Oncology #Cancer #Health #Medicine

🌟 𝗡𝗲𝘄 𝗥𝗲𝗹𝗲𝗮𝘀𝗲: “𝗪𝗵𝗮𝘁’𝘀 𝗡𝗲𝘄 𝗗𝗼𝗰? 𝗶𝗻 𝗚𝗜 𝗖𝗮𝗻𝗰𝗲𝗿” 🌟 Prof Marc Van den Eynde & Prof Eric Van Cutsem unveil new standards in HER2-Positive Gastric Cancer Treatment. This episode delves into the KEYNOTE-811 study's significant findings, demonstrating the enhanced efficacy and safety of combining pembrolizumab with trastuzumab and chemotherapy for HER2-positive gastric cancer patients. The study marks a milestone in cancer treatment, offering a beacon of hope for patients and setting new benchmarks for future therapies. 👇 Watch the full video  link in the comments! #MediMix #HER2Positive #GastricCancer #OncologyInnovation

🚨Highlights from ESMO 2024! Prof Dr Emmanuel Seront, medical oncologist at Cliniques Universitaires Saint-Luc, shares key findings from the mini oral session on non-prostate GU cancers: - SunRISe-1: TAR offers a promising new alternative to radical cystectomy in high-risk bladder cancer. - AMBASSADOR : Adjuvant pembrolizumab improves DFS following radical cystectomy in MIBC. - TACITO: FMT enhances the effectiveness of immunotherapy in renal cancer. Discover these updates.👇 For all ESMO 2024 videos, find the link in the comments! #MediMix #ESMO2024 #GUCancer #Oncology #BladderCancer #RenalCancer #CancerResearch #ClinicalTrials

New results are in! The phase 3 CROWN study compared lorlatinib, a brain-penetrant, third-generation ALK tyrosine kinase inhibitor, with crizotinib in treatment-naive patients with advanced ALK+ non-small cell lung cancer (NSCLC). After 5 years of follow-up, lorlatinib demonstrated remarkable efficacy and safety outcomes. Lorlatinib’s sustained efficacy and IC benefits underscore its potential as a first-line therapy for ALK+ NSCLC. Clinicians should consider these findings when tailoring treatment strategies. Exciting progress! Watch OncLive's video to learn more about the study from Massachusetts General Hospital's Dr. Ibiayi Dagogo-Jack. #LungCancer #PrecisionOncology #MedicalResearch https://lnkd.in/gWGWE-YV

𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗶𝗻 𝗥𝗲𝗰𝘂𝗿𝗿𝗲𝗻𝘁 𝗟𝗼𝘄-𝗚𝗿𝗮𝗱𝗲 𝗦𝗲𝗿𝗼𝘂𝘀 𝗢𝘃𝗮𝗿𝗶𝗮𝗻 𝗖𝗮𝗻𝗰𝗲𝗿 (𝗟𝗚𝗦𝗢𝗖) Today, we announced updated positive data from the Phase 2 RAMP 201 trial in recurrent LGSOC, which is one of the largest clinical trials ever conducted in this rare ovarian cancer. These results mark meaningful progress toward potentially offering a new combination therapy to patients in the U.S. The detailed findings will be presented today at the International Gynecologic Cancer Society (IGCS) Annual Meeting. 𝗟𝗲𝗮𝗿𝗻 𝗮𝗯𝗼𝘂𝘁 𝗮𝗹𝗹 𝘁𝗵𝗲 𝘂𝗽𝗱𝗮𝘁𝗲𝘀 𝗶𝗻 𝗼𝘂𝗿 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲: https://lnkd.in/edcr6sSU #VerastemOnc ##LGSOC #IGCS2024 #OvarianCancer

Recent advances in immunotherapy have sparked hope for patients with metastatic colorectal cancer. The NIH's pioneering research, demonstrating the potential of personalized cellular immunotherapy, emphasizes the critical requirement for high-quality biospecimens to advance this field. https://lnkd.in/e7hCSznR Email us at sales@bocabio.com to learn more about our CRC inventory #Immunotherapy #CancerResearch

🌟 𝗡𝗲𝘄 𝗘𝗽𝗶𝘀𝗼𝗱𝗲 𝗔𝗹𝗲𝗿𝘁: "𝗪𝗵𝗮𝘁’𝘀 𝗡𝗲𝘄 𝗗𝗼𝗰? 𝗶𝗻 𝗚𝗜 𝗖𝗮𝗻𝗰𝗲𝗿” 🌟   Join Prof Eric Van Cutsem and Prof Marc Van den Eynde in 'What's New Doc?' as they discuss the groundbreaking CodeBreak 300 trial, combining sotorasib with panitumumab in KRAS G12C mutated metastatic colorectal cancer patients. Tune in now!   👇 Watch all WND GI videos - link in the comments! #MediMix #GastricCancer #Immunotherapy #OncologyResearch

📰 #UpdateYourRefs ⚡New publication in The Lancet Oncology presenting the results of #ENZA-p Phase 2 Trial on 162 patients with metastatic castration-resistant #prostate cancer from 15 Australian hospitals. It reveals that combining #enzalutamide with [177Lu]Lu-PSMA-617 significantly improves the outcomes compared to enzalutamide alone, raising the median “prostate-specific antigen (PSA) progression-free survival” from 7.8 months to 13.0 months. ➡ https://lnkd.in/eAcSMRfG Louise Emmett #CancerResearch, #ScienceNews, #MedicalResearch, #Cancer, #HealthcareAdvances, #ProstateCancer #LancetOncology #NuclearMedicine

Insightful article shared by Clarivate for Life Sciences & Healthcare Oncology team published in Nature Drug Discovery!! Our authors mention in the article "Between 2023 and 2032, the market will become increasingly crowded, with novel drugs expected to gain approval." Click below to read more. #Clarivateoncology #oncology #targetedtherapy #HER2positive #triplenegative

Patients with inoperable limited-stage small cell lung cancer (LS-SCLC) are treated with chemoradiation, but prognosis is limited. In a trial with 730 such patients who had not experienced progression after chemoradiation, the checkpoint inhibitor durvalumab improved median overall survival compared with placebo (56 versus 33 months), without added toxicity. For patients with LS-SCLC who have not experienced progression after concurrent chemoradiation, we now recommend durvalumab consolidation. Find out What's New in #oncology: https://ow.ly/8nPV50SvxOa #ClinicalUpdates #meded